

## SAFE CHAIN SOLUTIONS, LLC

**Drug Supply Chain Security Act Document** Doc#00000020683**(TI) Transaction Information**

Drug Name, Strength, Dosage Form, Container Size: BIKTARVY 30CT, 50; 200; 25 mg/1; mg/1; mg/1, TABLET, 30 TABLET in 1 BOTTLE, PLASTIC (61958-2501-1)		
Reference Number: 01I43504		
NDC: 61958-2501-01		
Lot Number CDSFGA	Quantity 2	Unique Serial #

**(TH) Transaction History**

Manufacturer's Name: GILEAD SCIENCES, INC

Manufacturer's information 1800 WHEELER AVENUE LA VERNE, CA 91750

SOLD TO: Name: AMERISOURCEBERGEN DRUG CP Address: 5500 NEW HORIZONS BLVD. NORTH AMITYVILLE NY 11701-1156 Date Purchased & Ref : 08/23/19 A141310	SHIPPED TO: Name: AMERISOURCEBERGEN DRUG CP Address: 5500 NEW HORIZONS BLVD. NORTH AMITYVILLE NY 11701-1156 Date Received & Ref : 08/23/19 A141310
SOLD TO: Name: AMSTERDAM WELLNESS PHARMA Address: 2091 AMSTERDAM AVE NEW YORK NY 10032-8210 Date Purchased & Ref : 10/16/19 20191016	SHIPPED TO: Name: AMSTERDAM WELLNESS PHARMA Address: 2091 AMSTERDAM AVE NEW YORK NY 10032-8210 Date Received & Ref : 10/16/19 20191016
SOLD TO: Name: BOULEVARD 9229 LLC Address: 9229 QUEENS BLVD REGO PARK NY 11374 Date Purchased & Ref :	SHIPPED TO: Name: BOULEVARD 9229 LLC Address: 9229 QUEENS BLVD REGO PARK NY 11374 Date Received & Ref :
SOLD TO: Name: SAFE CHAIN SOLUTIONS, LLC Address: 822 CHESAPEAKE DR CAMBRIDGE MD 21613 Date Purchased & Ref : 02/22/21 PO#01212034	SHIPPED TO: Name: SAFE CHAIN SOLUTIONS Address: 822 CHESAPEAKE DR CAMBRIDGE MD 21613 Date Received & Ref : 02/23/21 RC#017227
SOLD TO: Name: PHARMAQUICK LLC Address: 753 ARTHUR GODFREY RD MIAMI BEACH FL 33140 Date Purchased & Ref : 02/23/21 01S38760002	SHIPPED TO: Name: PHARMAQUICK LLC Address: 753 ARTHUR GODFREY RD MIAMI BEACH FL 33140 Date Received & Ref : 02/23/21 01S38760002

**(TS) Transaction Statement:** This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) – (G)

- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.

GOVERNMENT  
EXHIBIT

18

1:24-cr-20255-WPD